Chronic heart failure with reduced ejection fraction(HFrEF)
Conditions
Interventions
None listed
Sponsors
Okayama university
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients who will be seen between the Ethics Committee approval and March 31, 2024. (2) Patients who are able to provide written consent to participate in the study of their own free will. (3) Patients whose age at the time of consent is 20 years or older. 4) Gender: male or female 5) Left ventricular ejection fraction (LVEF) <45% observed within 12 months 6) NYHA>=II degree 7) Patients undergoing standard treatment for chronic heart failure (viii) Patients scheduled to receive Vericiguat
Exclusion criteria
Exclusion criteria: (1) Women who are pregnant or may become pregnant (2) Patients with a history of hypersensitivity to Vericiguat (3) Patients receiving soluble guanylate cyclase (sGC) stimulator (riociguat) 3) Patients receiving soluble guanylate cyclase (sGC) stimulant (riociguat). 4) Other patients who are deemed unsuitable for this study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Right heart function indices by echocardiography at 24 weeks (RVFAC, RV diameter (base, mid, longitudinal), RV thickness, RV s', TAPSE) | — |
Secondary
| Measure | Time frame |
|---|---|
| NTproBNP (12 weeks, 24 weeks) High-sensitivity troponin T (12 weeks, 24 weeks) KCCQ (12 weeks, 24 weeks) NYHA (12 weeks, 24 weeks) Echocardiographic indices Vericiguat dose (12 weeks, 24 weeks, 1 year) Clinical outcomes (death, cardiovascular death, hospitalization for worsening heart failure) Incidence of adverse events | — |
Countries
Japan
Contacts
Public ContactHironobu Toda
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Department of Cardiovascular Medicine
Outcome results
None listed